Cargando…
Sensitization of neuroblastoma for vincristine-induced apoptosis by Smac mimetic LCL161 is attended by G2 cell cycle arrest but is independent of NFκB, RIP1 and TNF-α
We demonstrated sensitization for chemotherapy by Smac mimetic (SM) LCL161, a potent antagonist of inhibitor of apoptosis proteins (IAP), in neuroblastoma (NB). Vinca alkaloids, particularly vincristine (VCR), displayed the strongest impact on inhibition of proliferation and apoptosis induction in c...
Autores principales: | Langemann, Doerte, Trochimiuk, Magdalena, Appl, Birgit, Hundsdoerfer, Patrick, Reinshagen, Konrad, Eschenburg, Georg |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5675670/ https://www.ncbi.nlm.nih.gov/pubmed/29152118 http://dx.doi.org/10.18632/oncotarget.21193 |
Ejemplares similares
-
Smac mimetic LCL161 supports neuroblastoma chemotherapy in a drug class-dependent manner and synergistically interacts with ALK inhibitor TAE684 in cells with ALK mutation F1174L
por: Najem, Safiullah, et al.
Publicado: (2016) -
Smac mimetics LCL161 and GDC-0152 inhibit osteosarcoma growth and metastasis in mice
por: Shekhar, Tanmay M., et al.
Publicado: (2019) -
The SMAC mimetic LCL-161 selectively targets JAK2(V617F) mutant cells
por: Craver, Brianna M., et al.
Publicado: (2020) -
The SMAC mimetic, LCL-161, reduces survival in aggressive MYC-driven lymphoma while promoting susceptibility to endotoxic shock
por: West, A C, et al.
Publicado: (2016) -
Combining the SMAC mimetic LCL161 with Gemcitabine plus Cisplatin therapy inhibits and prevents the emergence of multidrug resistance in cholangiocarcinoma
por: Prasopporn, Sunisa, et al.
Publicado: (2022)